Please login to the form below

Not currently logged in
Email:
Password:

Celgene’s triple multiple myeloma therapy clears phase III trial

The biotech says the combo hit its OPTIMISMM primary endpoint

Celgene

US biotech Celgene has been a big player in the blood cancer space, most recently securing CHMP backing to expand its biggest-selling drug Revlimid as a maintence treatment for multiple myeloma patients.

Its presence in the field is showing no signs of wavering either, following new data from a pivotal phase III trial of Pomalyst whose results are looking good for Celgene.

Known as OPTIMISMM, the study evaluated the efficacy and safety of Pomalyst (pomalidomise) plus Takeda’s Velcade (bortezomib) and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

The trial is the only phase III study to date investigating a triple combination in patients who have all received prior therapy - Revlimid - and according to the biotech, this particular population of patients is witnessing a growing unmet medical need.

Although data is yet to be fully released, Paul Richardson, clinical programme leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center, said: “The OPTIMISMM results confirm the expanding role of pomalidomide in previously treated multiple myeloma patients.”

Celgene also claimed that the triple therapy achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival verses the comparator arm. The safety profile was also consistent with previously reported data.

Richardson added: “We see the PVd combination as an important step in improving care, and especially for patients previously treated with Revlimid in this setting.”

Pomalyst (pomalidomide) - Celgene’s second biggest earner - brought in $1.6bn for the biotech last year, an increase of 23% from $1.3bn seen in 2016.

Celgene are now hoping that its new triple therapy has the potential to boost sales even further in the multiple myeloma market if all goes well.

Article by
Gemma Jones

7th February 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics